After the fall – our take on Genmab

Peter Garnry

Head of Equity Strategy
Peter Garnry joined Saxo Bank in 2010 and is Head of Equity Strategy. In 2016, he became responsible for the quantitative strategies team, which focuses on how to apply computer models to financial markets. He develops trading strategies and analyses of the equity markets as well as individual company stocks applying statistics and models.

Europe’s largest biotechnology company Genmab is down 20% today after opening 25% lower as one of its key studies on cancer treatments is stopped. This is obviously a big blow to their efforts in the combo trials (mixing drugs for cancer treatments) and investors were hoping for a blockbuster potential in this study. 

The stock has a neutral rating in our proprietary Equity Radar model with value being the worst contributor (expensive stock). We have just rerun the model and today’s decline is pushing up the value, yield and reversal factors, so our model is now signalling a positive stance on the stock. 

Genmab share price. Chart source: Bloomberg


Saxo Capital Markets (Australia) Pty Ltd prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed you initial investment.

Please refer to our Analysis Disclaimer, and our Combined Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at